Recall
FDAHealthDecember 6, 2024

Amerisource Health Services LLC — Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Labo

⚠️ CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
December 6, 2024

Nationwide in the USA

What's affected?

Product
Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08
Lot code
s

Additional details

Lots, expiry: Lot DT6022166A, exp 11/30/2024; Lot DT6023071A, exp 2/28/2025

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 1,815 bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.